# A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

> **NCT03442764** · PHASE2 · COMPLETED · sponsor: **MyoKardia, Inc.** · enrollment: 59 (actual)

## Conditions studied

- Non-obstructive Hypertrophic Cardiomyopathy

## Interventions

- **DRUG:** mavacamten
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03442764
- **Lead sponsor:** MyoKardia, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-30
- **Primary completion:** 2020-01-07
- **Final completion:** 2020-01-07
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2022-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03442764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03442764, "A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03442764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*